Compare Adaptive Biotechnologies Corp (ADPT) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wayfair Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while Wayfair Inc trades at $103.55 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 3.5× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Wayfair Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | W | |
|---|---|---|
Market Cap | $4.05B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $119.05 |
52-Week Low | $12.30 | $57.40 |
Enterprise Value | $4.12B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Wayfair (W) trades at $106.59, up 2.44% today, showing strong momentum following better-than-expected Q2 2026 earnings. Technical indicators signal a bullish trend with the stock approaching key resistance levels. Fundamentally, the company delivered 7.5% year-over-year revenue growth in Q2 2026, though it continues to operate at a net loss margin of -2.49%. Recent news highlights strong U.S. segment performance and market share gains despite international challenges.
The outlook remains cautiously optimistic with analysts projecting 51.78% buy ratings and a $122 consensus price target, representing 14.4% upside potential. Key risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and uneven consumer demand. The stock's premium valuation at 151.17x EV/EBITDA requires continued execution on growth and margin expansion targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
